Hyman David M, Taylor Barry S, Baselga José
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Cell. 2017 Feb 9;168(4):584-599. doi: 10.1016/j.cell.2016.12.015.
Early successes in identifying and targeting individual oncogenic drivers, together with the increasing feasibility of sequencing tumor genomes, have brought forth the promise of genome-driven oncology care. As we expand the breadth and depth of genomic analyses, the biological and clinical complexity of its implementation will be unparalleled. Challenges include target credentialing and validation, implementing drug combinations, clinical trial designs, targeting tumor heterogeneity, and deploying technologies beyond DNA sequencing, among others. We review how contemporary approaches are tackling these challenges and will ultimately serve as an engine for biological discovery and increase our insight into cancer and its treatment.
在识别和靶向个体致癌驱动因素方面取得的早期成功，以及对肿瘤基因组进行测序的可行性不断提高，带来了基因组驱动的肿瘤治疗的前景。随着我们扩大基因组分析的广度和深度，其实施过程中的生物学和临床复杂性将是前所未有的。挑战包括靶点鉴定与验证、实施联合用药、临床试验设计、应对肿瘤异质性以及应用DNA测序以外的技术等。我们回顾了当代方法如何应对这些挑战，并最终将成为生物学发现的引擎，加深我们对癌症及其治疗的理解。
